• Summit Therapeutics partnered with ECOG-ACRIN on EA2251, a registration-enabling Phase II/III trial of ivonescimab for first-line advanced biliary tract cancer.
• The study will compare ivonescimab with pembrolizumab or durvalumab, each combined with chemotherapy, with overall survival as the primary endpoint.
• US clinical trial site activations are expected to begin in the fourth quarter of 2026.
• Akeso’s China-based Phase III HARMONi-GI1 trial previously showed ivonescimab with chemotherapy improved survival over durvalumab with chemotherapy in biliary tract cancer.
• Detailed HARMONi-GI1 results will be presented October 25 at the European Society for Medical Oncology 2026 Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210605BIZWIRE_USPR_____20261021_BW853587) on October 21, 2026, and is solely responsible for the information contained therein.